SERF1A
Small EDRK-rich factor 1
Also known as: 4F5, FAM2A, FAM2B, H4F5, H4F5C, SERF1, SERF1_HUMAN, SERF1B, SMAM1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O75920
- Gene
- SERF1A
- Ensembl
- ENSG00000172058
- Chromosome
- 5
- Canonical length
- 110 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nuclear bodies
OverviewNCBI Gene
This gene is part of a 500 kb inverted duplication on chromosome 5q13. This duplicated region contains at least four genes and repetitive elements which make it prone to rearrangements and deletions. The repetitiveness and complexity of the sequence have also caused difficulty in determining the organization of this genomic region. The duplication region includes both a telomeric and a centromeric copy of this gene. Deletions of this gene, the telomeric copy, often accompany deletions of the neighboring SMN1 gene in spinal muscular atrophy (SMA) patients, and so it is thought that this gene may be a modifier of the SMA phenotype. The function of this protein is not known; however, it bears low-level homology with the RNA-binding domain of matrin-cyclophilin, a protein which colocalizes with small nuclear ribonucleoproteins (snRNPs) and the SMN1 gene product. Alternatively spliced transcripts have been documented but it is unclear whether alternative splicing occurs for both the centromeric and telomeric copies of the gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
110 residues, UniProt reviewed canonical sequence.
>O75920|SERF1A
1 MARGNQRELA RQKNMKKTQE ISKGKRKEDS LTASQRKQSS GGQKSESKMS AGPHLPLKAP
61 RENPCFPLPA AGGSRYYLAY GSITPISAFV FVVFFSVFFP SFYEDFCCWILocalizationUniProt · AlphaFold · HPA
Whether an antibody against SERF1A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.62
- Highest tissue expression
- 134 nTPM
Expression across tissuesHPA
Tissue
- testis: 134 nTPM
- retina: 60 nTPM
- cerebral cortex: 54 nTPM
- amygdala: 52 nTPM
- midbrain: 52 nTPM
- basal ganglia: 50 nTPM
Single-cell type
- brain excitatory neurons: 2.5 nCPM
- bergmann glia: 2.2 nCPM
- other brain neurons: 2.2 nCPM
- brain inhibitory neurons: 2.1 nCPM
- oligodendrocyte progenitor cells: 2 nCPM
- astrocytes: 1.7 nCPM
Immune cell
- eosinophil: 10 nTPM
- memory CD8 T-cell: 5.1 nTPM
- T-reg: 3.5 nTPM
- memory B-cell: 3.4 nTPM
- NK-cell: 3.2 nTPM
- gdT-cell: 3 nTPM
Brain region
- cerebral cortex: 13 nTPM
- hypothalamus: 12 nTPM
- white matter: 11 nTPM
- medulla oblongata: 11 nTPM
- basal ganglia: 11 nTPM
- amygdala: 11 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.88
- gnomAD pLI
- 0.3
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SERF1A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SERF1A as an antibody target. Whether an autoantibody or antibody against SERF1A could matter depends on whether native SERF1A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SERF1A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SERF1A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...